News | Heart Valve Technology | November 02, 2018

Valve Replacement Volume Key to Successful Patient Outcomes

New study finds patient outcomes are best at healthcare facilities that perform high volumes of both surgical and transcatheter aortic valve replacements

Valve Replacement Volume Key to Successful Patient Outcomes

November 2, 2018 — Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to adopt a newer, less invasive technique, according to a new study, published Oct. 31 in JAMA Cardiology from Weill Cornell Medicine.1 When hospitals have a high caseload of both, they are likely to achieve the best patient outcomes for those who undergo the newer procedure.

“You can imagine that hospitals known for valve care are more likely to attract valve patients and adopt TAVR [transcatheter aortic valve replacement] more quickly,” said senior author Art Sedrakyan, M.D., Ph.D., a professor of healthcare policy and research at Weill Cornell Medicine. “And it’s likely that the more experience the hospitals have in performing valve surgery, the better patient outcomes are.”

In the study, the investigators sought to examine the relationship between the number of times hospitals perform the established procedure, called surgical aortic valve replacement (SAVR), and patient outcomes from the less invasive TAVR. TAVR has gained popularity in recent years, as it allows surgeons to deliver a valve replacement using only a catheter. TAVR was first approved in 2011 for high-risk patients who were considered inoperable.

Recently, the Centers for Medicare & Medicaid Services (CMS) set criteria to promote high-quality implementation of TAVR, including the requirement that hospitals perform at least 50 SAVR procedures a year prior to beginning TAVR procedures. Due to scrutiny over the requirements, a Medicare Evidence Development & Coverage Advisory Committee panel took place in July to discuss the issue. While some attendees argued for lowering the requirements, as they are difficult to reach in less populated areas, others posited that hospitals with high SAVR numbers would have lower complication rates for TAVR.

To discern that relationship, the Weill Cornell Medicine team, led by Sedrakyan, analyzed more than 60,000 TAVR procedures performed at hospitals between 2011 and 2015. They ultimately found that high volumes of both procedures was associated with the best outcomes for TAVR.

“It’s important that we evaluate TAVR and SAVR in a conjoined way. That’s what makes this study novel – previous studies have not assessed the effect of SAVR volume,” said first author Jialin Mao, M.D., an instructor in healthcare policy and research at Weill Cornell Medicine.

When researchers looked at patient mortality rates 30 days and then one year after undergoing TAVR, they found that patients treated at hospitals with high SAVR volume and high TAVR volume had the lowest mortality. “Patients need to know that getting care at institutions with the highest volume of aortic valve interventional care is most beneficial to them,” Sedrakyan said.

The findings suggest that federal requirements determining hospital eligibility for Medicare and Medicaid reimbursement for TAVR procedures are appropriate and could even be more restrictive.

“Current restrictions need to be maintained and made even stronger,” Sedrakyan said. “We don’t believe the time is right for widespread access to these technologies at the expense of patient safety.”

For more information: www.jamanetwork.com/journals/jamacardiology

Reference

1. Mao J., Redberg R.F., Carroll J.D., et al. Association Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes. JAMA Cardiology, published online Oct. 31, 2018. doi:10.1001/jamacardio.2018.3562

Related TAVR Content

Higher Volume of TAVR Boosts Key In-Hospital Outcomes

VIDEO: Impact of TAVR Procedural Volume on Patient Outcomes at ACC.16


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now